Enanta Pharmaceuticals Inc (ENTA)

[willyw]

I was drawn into investing thru HCV.
Gilead paid 11 billion for a fabulous asset and generated a lot of income.
The only *problem* (some thought) it was a cure, and in time the treatment numbers dropped.

Covid on the other hand spins off variants that evade current vaccines.
Thus Covid may have a longer run than initially expected and repeat customers.

W/ regards to HCV, Enanta had little leverage and didn't get a large share in HCV profits.
It may be that this recent Covid surge- if there is continued negotiation w/ a potential partner- this surge may be a benefit.
Maybe Enanta won't accept a first low ball offer.
(that's a reason I wondered if they pulled the preclinical candidate from their slides)
No announced agreement doesn't equal failure- it may mean a better offer coming.
Rising Covid hospitalizations are probably also be getting investor's attention.

Not only has the share price come up the volume is encouraging too.